Join us on Wednesday, March 10^th for this CME/MOC-accredited webinar
7:00 PM – 8:00 PM ET

This activity is supported by an educational grant from Astellas.

Wednesday, March 10, 2021
7:00 PM – 8:00 PM Eastern Time
Live CME/MOC-accredited webinar

Overview
To provide a framework for the discussion of available research, including data introduced during the 2020 ASH Annual Meeting, participating faculty will present cases from their practices and address questions related to patient care. The agenda below is designed to show how the proceedings will unfold and the types of cases and topics to be covered. A final agenda will be provided in the coming weeks to include faculty cases and questions.

SAMPLE CASE: An older patient with newly diagnosed acute myeloid leukemia (AML) who is not eligible for intensive induction chemotherapy

Discussion Questions

• What proportion of patients with newly diagnosed AML are ineligible for or refuse intensive up-front treatment?
• What data led to the approval of venetoclax in combination with a hypomethylating agent (HMA) or low-dose cytarabine (LDC) as first-line therapy for older patients or those ineligible for intensive induction chemotherapy?
• What factors generally influence your selection of a therapeutic partner for venetoclax for AML?
• How do you approach initial dosing of venetoclax in combination with an HMA or LDC for newly diagnosed AML?
• How do you approach tumor lysis syndrome in patients receiving venetoclax?
• What are the most common side effects that you see in patients with AML receiving venetoclax-based therapy?
• What is the FDA-approved indication for glasdegib? For which patients are you employing this agent rather than a venetoclax-based combination?
• What data emerging at ASH 2020 further inform the way you intend to utilize venetoclax or glasdegib?

SAMPLE CASE: A patient with relapsed/refractory (R/R) AML with a FLT3 mutation

Discussion Questions

• How does the presence of a FLT3 mutation affect prognosis?
• What side effects are most problematic for patients receiving midostaurin? How do the toxicities associated with midostaurin compare to what has been reported with next-generation FLT3 inhibitors, such as gilteritinib and quizartinib?
• What outcomes have been observed with venetoclax-based therapy for patients with FLT3 mutations?
• What were the endpoints of the ADMIRAL trial comparing gilteritinib to salvage chemotherapy for patients with R/R AML with FLT3 mutations?
• What preliminary data have been reported with gilteritinib and induction/consolidation chemotherapy for patients with newly diagnosed AML?
• In what situations, if any, would you offer maintenance therapy with a FLT3 inhibitor to a patient who attained a response to induction and consolidation treatment?
• What preliminary data have been reported with quizartinib and crenolanib?
• What data emerging at ASH 2020 further inform the way you intend to manage AML with a FLT3 mutation?

SAMPLE CASE: An older patient with newly diagnosed AML with an IDH1 mutation

Discussion Questions

• What data led to the FDA approval of ivosidenib for newly diagnosed AML with an IDH1 mutation? What outcomes have been observed with venetoclax combinations for patients with IDH mutations? What about glasdegib (with LDC)?
• How would you compare the efficacy and tolerability of venetoclax-based treatment to that of ivosidenib monotherapy?
• How would you approach therapy for this patient if they had an IDH2 mutation?
• How are you incorporating enasidenib into the management of AML with an IDH2 mutation?
• How does differentiation syndrome present in patients receiving ivosidenib or enasidenib?
• What data emerging at ASH 2020 further inform the way you intend to manage AML with an IDH mutation?

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of acute myeloid leukemia (AML).

Learning Objectives
Upon completion of this activity, participants should be able to

• Evaluate the importance of age, performance status and other biologic and disease-related factors in the selection and sequencing of therapy for patients with various presentations of AML.
• Appreciate the FDA approval of venetoclax in combination with azacitidine, decitabine or low-dose cytarabine for patients with newly diagnosed AML not eligible for intensive therapy, and identify individuals who may be appropriate for treatment with this novel agent.
• Reflect on available research evidence with approved and emerging FLT3 inhibitors, and use this information to guide clinical care and protocol opportunities for appropriate patients with newly diagnosed or progressive AML harboring a FLT3 mutation.
• Develop an understanding of the mechanism of action of, published data with and current clinical role of available IDH1/2 inhibitors for patients with AML and IDH1 or 2 mutations.
• Recognize the mechanisms of action, efficacy and safety of approved and investigational agents for the treatment of AML and other targetable genetic abnormalities to determine the current and potential utility of each in clinical practice.
• Design a plan of care to recognize and manage side effects and toxicities associated with current and recently approved systemic therapies for AML to support quality of life and continuation of treatment.
• Recall promising agents and combination strategies under investigation for AML, and counsel appropriately selected patients regarding clinical trial enrollment.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr Perl — Advisory Committee: AbbVie Inc, Actinium Pharmaceuticals Inc, Astellas, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, Daiichi Sankyo Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Syndax Pharmaceuticals Inc; Consulting Agreements: AbbVie Inc, Astellas, Daiichi Sankyo Inc, FORMA Therapeutics, Onconova Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc; Contracted Research (All Monies to Institution): AbbVie Inc, Actinium Pharmaceuticals Inc, Astellas, Daiichi Sankyo Inc, FUJIFILM Pharmaceuticals USA Inc; Data and Safety Monitoring Board/Committee: Beat AML LLC, Leukemia & Lymphoma Society. Dr Wang — Advisory Committee: AbbVie Inc, Astellas, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, GlaxoSmithKline, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, MacroGenics Inc, Novartis, Pfizer Inc, PTC Therapeutics, Stemline Therapeutics Inc, Takeda Oncology; Data and Safety Monitoring Board/Committee: AbbVie Inc, Rafael Pharmaceuticals Inc; Speakers Bureau: DAVA Oncology, Kura Oncology, Pfizer Inc, Stemline Therapeutics Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporter
This activity is supported by an educational grant from Astellas.